Company intelligence / Profile preview
Asia Cell Therapeutics
Shanghai, Chinaasiacgt.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Currently conducting Phase I clinical trials for burns & COPD treatments, and Phase II clinical trials for ankylosing spondylitis, liver cirrhosis & acute respiratory distress disorder. Received positive pre-IND responses from FDA for AS treatment. Planning to apply for IND to China NMPA and/or US FDA from 2025 Q1 for iPSC-derived cell therapeutic products.
- Therapeutic areas
- GastroenterologyPulmonologyDermatologyRheumatology
- Modalities
- Cell therapyGene therapyStem cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Asia Cell Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asia Cell Therapeutics.